Notice of stabilization measures in ChromoGenics during the period 23 March to 21 April 2017 on Nasdaq First North, Stockholm

Regulatory information
  • 2017-04-24
  • Press release
NOT FOR DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, TO NEW DISTRIBUTORS IN THE UNITED STATES OR FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION OR RELEASE WOULD BE ILLEGAL BY APPLICABLE LAW

 
ChromoGenics AB (publ) announces that stabilizing trading by Erik Penser AB ("EPB") in ChromoGenics’ shares on Nasdaq First North, Stockholm has ended.
The stabilization period in connection with the listing of the shares in ChromoGenics AB on Nasdaq First North Stockholm commenced on March 23, 2017 and ended on April 21, 2017. During the period, stabilization acquisitions totaled 121,312 shares. The stabilization period is completed and no further stabilization transactions will be implemented.

EPB, acting as stabilization firm, has announced that stabilization trading has been carried out, in accordance with Article 5 (4) of the EU Market Use Regulation 596/2014, on Nasdaq Stockholm as follows:

Stabilizing Information:
Issuer: ChromoGenics AB (publ)
Instrument: Stocks (ISIN SE0009496268)
Outcome of the Offer: 13,921,312 shares, of which stabilization max 121 312 shares
Offer Price: 8.50 SEK per share
Ticker: CHRO
Stabilization firm: Erik Penser Bank AB (publ)

Stabilizing Trading

    Price   Price   Price
Date Quantity (highest) (lowest) (average) Currency Market place
2017-03-23 85 500 8,20  6,30   6,71    SEK    Nasdaq First North
2017-03-24 2 000 6,20  6,20   6,20    SEK    Nasdaq First North
2017-03-27 12 000 6,80  6,30   6,60    SEK    Nasdaq First North
2017-03-28 5 000 6,50  6,35   6,44    SEK        Nasdaq First North
2017-03-29   812  6,55   6,40   6,46    SEK    Nasdaq First North
2017-03-30 - -   - -     - -
2017-03-31 - -     - -     - -
2017-04-03 - -   - -     - -
2017-04-04 - -   - -     - -
2017-04-05 2 000 7,20  7,20   7,20    SEK    Nasdaq First North
2017-04-06 - -   - -     - -
2017-04-07 4 000 7,35  7,25   7,30    SEK    Nasdaq First North
2017-04-10 1 000 7,25  7,25   7,25    SEK    Nasdaq First North
2017-04-11 9 000 7,40  7,30   7,34    SEK    Nasdaq First North
2017-04-12 - -   - -     - -
2017-04-13 - -   - -     - -
2017-04-18 - -   - -     - -
2017-04-19 - -   - -     - -
2017-04-20 - -   - -     - -
2017-04-21 - -   - -     - -


G&W Fondkommission is the financial advisor to ChromoGenics in connection with the transaction and appointed as Certified Adviser.

Contact:
Thomas Almesjö, CEO
Susanne Andersson, CFO & Head of Communications
Tel: +46 18 430 0430
E-mail: info@chromogenics.com

This information is such that ChromoGenics AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and according to the Act (1991:980) regarding trading with financial instruments. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET on April 24, 2017.
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

About ChromoGenics
ChromoGenics is a leader in dynamic glass with controllable heat- and light transmission. The company’s unique electrochromic technology ConverLight™, provides sustainable solar control with increased indoor comfort and energy efficiency. In 2016 the company started commercial sales to real estate projects in Scandinavia.

ChromoGenics is located in Uppsala and has about 20 employees. The technology is derived from the world leading research center at Ångström Laboratory at Uppsala University. The plant has been partly financed by a conditional loan from the Swedish Energy Agency. ChromoGenics share (CHRO) is listed on Nasdaq First North Stockholm with G&W Fondkommission as Certified Adviser. 

Important information
Publication and distribution of this announcement may in certain jurisdictions be restricted by law and persons in those jurisdictions where this press release has been published or distributed should inform themselves about and observe such restrictions. The information in this press release is not an offer to purchase, subscribe for or otherwise trade in shares or other securities in ChromoGenics.

This press release is not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa or other country where such action would require additional measures in addition to those following Swedish law or where this would contravene the laws or regulations of that country. The information in this press release may not be forwarded, reproduced or disclosed in ways that conflict with such restrictions. Failure to comply with this instruction may result in violation of the United States Securities Act of 1933 (the "Securities Act") as amended, or applicable laws in other jurisdictions.



PRESS RELEASES